Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 17 04:00PM ET
11.51
Dollar change
0.00
Percentage change
0.00
%
Index- P/E- EPS (ttm)-18.25 Insider Own11.14% Shs Outstand4.16M Perf Week-18.43%
Market Cap46.73M Forward P/E- EPS next Y-4.67 Insider Trans-43.57% Shs Float3.61M Perf Month-1.88%
Income-69.77M PEG- EPS next Q-1.90 Inst Own64.95% Short Float8.00% Perf Quarter-1.62%
Sales48.73M P/S0.96 EPS this Y40.03% Inst Trans-66.79% Short Ratio2.30 Perf Half Y27.76%
Book/sh4.53 P/B2.54 EPS next Y51.21% ROA-31.41% Short Interest0.29M Perf Year-53.49%
Cash/sh28.74 P/C0.40 EPS next 5Y- ROE-157.63% 52W Range8.25 - 28.44 Perf YTD5.11%
Dividend Est.- P/FCF- EPS past 5Y7.97% ROI-262.43% 52W High-59.53% Beta1.58
Dividend TTM- Quick Ratio2.73 Sales past 5Y101.03% Gross Margin83.06% 52W Low39.52% ATR (14)1.15
Dividend Ex-Date- Current Ratio2.73 EPS Y/Y TTM56.27% Oper. Margin-130.74% RSI (14)39.94 Volatility7.71% 8.11%
Employees109 Debt/Eq1.66 Sales Y/Y TTM94.15% Profit Margin-143.18% Recom1.40 Target Price35.80
Option/ShortNo / Yes LT Debt/Eq0.41 EPS Q/Q47.27% Payout- Rel Volume0.00 Prev Close11.51
Sales Surprise-43.56% EPS Surprise-98.29% Sales Q/Q-33.59% EarningsMar 27 BMO Avg Volume125.51K Price11.51
SMA20-14.11% SMA50-11.30% SMA200-10.60% Trades Volume0 Change0.00%
Date Action Analyst Rating Change Price Target Change
Jun-17-22Initiated BMO Capital Markets Outperform $7
Jun-09-22Downgrade William Blair Outperform → Mkt Perform
Jul-27-20Resumed BTIG Research Buy $16
Apr-03-20Downgrade Goldman Buy → Neutral $24 → $7
Mar-05-20Initiated Stifel Buy $21
Feb-25-20Initiated William Blair Outperform
Aug-09-19Initiated BTIG Research Buy $22
Jul-16-19Initiated H.C. Wainwright Buy $21
Apr-22-19Initiated JP Morgan Overweight
Apr-22-19Initiated Jefferies Buy
Apr-16-24 04:15PM
Apr-11-24 09:55AM
Apr-02-24 09:55AM
06:48AM
Mar-27-24 11:53AM
08:10AM Loading…
08:10AM
07:07AM
06:45AM
Mar-20-24 04:30PM
Mar-19-24 07:00AM
Mar-14-24 08:15AM
Mar-06-24 08:45AM
Mar-01-24 06:30AM
Feb-29-24 04:01PM
09:22AM
04:25AM Loading…
Feb-27-24 04:25AM
Feb-20-24 07:00AM
Feb-14-24 07:00AM
Feb-13-24 07:00AM
Feb-12-24 07:00AM
Feb-09-24 07:00AM
Jan-09-24 07:00AM
07:00AM
Dec-13-23 08:20AM
Dec-04-23 07:00AM
Nov-30-23 07:00AM
Nov-28-23 07:00AM
Nov-14-23 08:55AM
Nov-13-23 07:05AM
Nov-10-23 07:00AM
07:00AM Loading…
Nov-09-23 07:00AM
Nov-07-23 07:54AM
07:17AM
07:00AM
Nov-01-23 07:00AM
Oct-26-23 07:30AM
Oct-23-23 07:00AM
Oct-12-23 08:00AM
Sep-27-23 07:00AM
Sep-12-23 07:00AM
Sep-06-23 07:00AM
Aug-31-23 07:00AM
Aug-22-23 07:32AM
07:32AM
Aug-18-23 09:35AM
Aug-15-23 07:04PM
Aug-06-23 08:03AM
Aug-04-23 08:35AM
07:23AM
07:15AM
Aug-01-23 05:00PM
Jul-27-23 07:30AM
Jul-13-23 01:03PM
Jun-22-23 07:00AM
Jun-05-23 07:00AM
May-31-23 07:15AM
May-25-23 07:00AM
May-24-23 08:00AM
May-19-23 07:00AM
May-12-23 05:06PM
May-09-23 08:15AM
07:21AM
07:00AM
May-08-23 04:30PM
May-02-23 07:00AM
Apr-20-23 08:00AM
Apr-19-23 04:22PM
Apr-17-23 07:34AM
Apr-13-23 07:00AM
Mar-27-23 07:00AM
Mar-09-23 08:15AM
07:00AM
Mar-07-23 06:33AM
Mar-02-23 07:00AM
Feb-24-23 07:00AM
Feb-22-23 07:00AM
Feb-14-23 07:00AM
Jan-20-23 08:13AM
Jan-09-23 07:30AM
Jan-06-23 07:00AM
Dec-10-22 10:00AM
Nov-11-22 10:04AM
Nov-10-22 05:00PM
Nov-08-22 08:25AM
07:00AM
Nov-04-22 07:19PM
Nov-03-22 09:40AM
Nov-02-22 07:00AM
Oct-26-22 07:00AM
Oct-25-22 06:40AM
Oct-11-22 03:00AM
Sep-28-22 06:08AM
Sep-22-22 07:00AM
Sep-07-22 07:00AM
Sep-02-22 07:00AM
Aug-13-22 09:06AM
Aug-10-22 10:57AM
Aug-08-22 08:25AM
07:00AM
Aug-04-22 12:39PM
Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's proprietary genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane on January 26, 2006 and is headquartered in Durham, NC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SMITH J. JEFFERSONChief Research OfficerJan 23 '24Sale0.3728,00010,3601,987,269Jan 23 07:11 PM
Amoroso MichaelPresident and CEOJan 22 '24Sale0.36137,39049,460356,433Jan 23 07:17 PM
List AlanChief Medical OfficerJan 22 '24Sale0.3621,5267,74994,982Jan 23 07:13 PM
Scimeca DarioGeneral Counsel and SecretaryJan 22 '24Sale0.3621,2877,663151,028Jan 23 07:15 PM
Amoroso MichaelPresident and CEONov 03 '23Sale0.40125,02550,010227,103Nov 06 05:07 PM
Scimeca DarioGeneral Counsel and SecretaryNov 03 '23Sale0.4016,0236,409112,970Nov 06 05:09 PM
Scimeca DarioGeneral Counsel and SecretaryJun 08 '23Sale0.7513,36110,02168,473Jun 09 04:15 PM
List AlanChief Medical OfficerApr 27 '23Sale0.797,7716,13956,496Apr 28 04:53 PM